Merck KGaA (OTCMKTS:MKKGY) Sees Unusually-High Trading Volume – Should You Buy?

Merck KGaA (OTCMKTS:MKKGY) shares saw an uptick in trading volume on Monday . 164,620 shares were traded during mid-day trading, an increase of 71% from the previous session’s volume of 96,264 shares.The stock last traded at $31.5910 and had previously closed at $31.58.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on MKKGY shares. HSBC upgraded shares of Merck KGaA to a “hold” rating in a research report on Monday, July 6th. Jefferies Financial Group began coverage on shares of Merck KGaA in a research note on Tuesday, May 26th. They set a “hold” rating on the stock. Finally, Zacks Research raised shares of Merck KGaA from a “hold” rating to a “strong-buy” rating in a report on Wednesday, July 22nd. One research analyst has rated the stock with a Strong Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Merck KGaA presently has an average rating of “Hold”.

Merck KGaA Trading Down 0.0%

The business has a 50 day moving average price of $32.18 and a 200 day moving average price of $29.30. The company has a current ratio of 1.51, a quick ratio of 1.00 and a debt-to-equity ratio of 0.36. The company has a market capitalization of $20.40 billion, a P/E ratio of 16.28, a PEG ratio of 2.61 and a beta of 0.98.

About Merck KGaA

Merck KGaA, Darmstadt, Germany, commonly referred to as Merck Group, is a multinational science and technology company with origins dating back to 1668. The company develops and manufactures products and technologies across healthcare, life science and electronics applications. It is distinct from the U.S. pharmaceutical company Merck & Co; Merck KGaA is a European group headquartered in Darmstadt and is publicly listed in Germany with an OTC American depositary receipt available under the symbol MKKGY.

Merck’s Healthcare business develops prescription medicines and related services focused on areas such as oncology, immunology, neurology (including therapies for multiple sclerosis) and fertility.